8JD Stock Overview
Engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Valbiotis SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.30 |
| 52 Week High | €6.70 |
| 52 Week Low | €3.46 |
| Beta | -0.32 |
| 1 Month Change | 12.42% |
| 3 Month Change | 6.97% |
| 1 Year Change | 18.78% |
| 3 Year Change | -40.44% |
| 5 Year Change | n/a |
| Change since IPO | -45.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8JD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | 0.4% | 0.6% |
| 1Y | 18.8% | -23.7% | 5.4% |
Return vs Industry: 8JD exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 8JD exceeded the German Market which returned 7.3% over the past year.
Price Volatility
| 8JD volatility | |
|---|---|
| 8JD Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8JD has not had significant price volatility in the past 3 months.
Volatility Over Time: 8JD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 48 | Sebastien Peltier | www.valbiotis.com |
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD.
Valbiotis SA Fundamentals Summary
| 8JD fundamental statistics | |
|---|---|
| Market cap | €66.72m |
| Earnings (TTM) | -€7.37m |
| Revenue (TTM) | €6.81m |
9.8x
P/S Ratio-9.1x
P/E RatioIs 8JD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8JD income statement (TTM) | |
|---|---|
| Revenue | €6.81m |
| Cost of Revenue | €2.04m |
| Gross Profit | €4.77m |
| Other Expenses | €12.13m |
| Earnings | -€7.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Oct 29, 2024
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 69.98% |
| Net Profit Margin | -108.21% |
| Debt/Equity Ratio | 57.6% |
How did 8JD perform over the long term?
See historical performance and comparison